Business Model Breakdown
How Spectral AI Inc Makes Money
MDAI
Market Cap
$60M
Annual Revenue
$20M
Profit Margin
-38.5%
Employees
78
The Short Version
Spectral AI develops and intends to commercialize the DeepView System, an advanced AI-powered diagnostic device designed to accurately assess wound healing and severity, with an initial focus on burn injuries. Currently, the company primarily generates revenue through substantial government R&D contracts, most notably from the Biomedical Advanced Research and Development Authority (BARDA), which funds the ongoing development, validation, and advanced procurement of its technology. In the future, Spectral AI aims to shift towards generating revenue through direct sales and potentially licensing agreements for its DeepView system to hospitals, burn centers, and clinics, transitioning from a grant-funded R&D model to a commercial hardware-plus-AI-software-as-a-service model.
Where the Revenue Comes From
R&D contracts (e.g., BARDA, ~100% of current revenue, expected $18.5M in FY26)
Future product sales/licensing of DeepView System hardware and software to healthcare providers
Who buys: Government agencies (e.g., BARDA), future customers include hospitals, burn centers, and other clinical settings for wound diagnostics.
Why It Works (Competitive Advantages)
- ✔FDA-cleared DeepView System for wound assessment
- ✔Significant BARDA contract funding and validation
- ✔Proprietary AI algorithms and intellectual property
- ✔First-mover advantage in specialized AI burn diagnostics
Economic Moat: Narrow (Intangible Assets/IP (Proprietary AI and algorithms), Regulatory Hurdles/Switching Costs (FDA clearance, BARDA validation, and integration into clinical workflows create high barriers to entry))
What Our Analysis Says
DVR Score as of April 18, 2026
Spectral AI (MDAI) continues to present a high-risk, high-reward investment profile, with recent developments positively impacting its short-term financial viability. The company's cutting-edge AI-driven wound diagnostics, FDA-cleared and BARDA-validated DeepView System, addresses a significant unmet market need, offering substantial scalability and a robust competitive moat through regulatory approvals and intellectual property, positioning it for potential market leadership in its niche. Critically, the cash position has significantly improved to $15.4 million, supplemented by an additional $31.7 million in BARDA funding, substantially mitigating previous concerns about a very short cash runway. Furthermore, the submission of a De Novo 510(k) for burn diagnostics signals progress towards broader commercialization. While FY25 revenue declined and overall profitability remains a challenge with negative shareholder equity, these positive financial and regulatory advancements de-risk the immediate outlook, justifying an increased score. Continued execution on BARDA, successful De Novo approval, and accelerating commercial sales are now paramount for realizing its growth potential, which remains contingent on significant capital beyond existing funding for full scale-up.